Effectiveness of vaccination (Sinopharm) among Covid-19 positive patients in a tertiary care hospital

Document Type : Original Articles

Authors

1 Shaikh Khalifa Bin Zayed Al Nahyan/CMH Teaching Hospital (Poonch Medical College), Rawalakot Pakistan

2 Islamabad Medical and Dental College, Islamabad Pakistan

3 Combined Military Hospital (CMH), Bahawalpur Pakistan

4 CMH Kharian Medical College, Kharian Pakistan

10.32592/ARI.2024.79.5.967

Abstract

The SARS-CoV-2, has caused a pandemic of acute respiratory disease, ‘coronavirus disease 2019’ (Covid-19), posed a major threat to health and the international economy during past few years. It is believed that vaccine can stop the rapid spread of the disease. The aim of this study was to evaluate the effect of the Sinopharm vaccine in terms of mortality and severity of the disease among Covid-19 positive patients.
This observational cross-sectional study was done at the Department of Medicine and Department of Pathology Shaikh Khalifa Bin Zayed Al-Nahyan/CMH Teaching Hospital (Poonch Medical College), Rawalakot AJK Pakistan from July 2021 to September 2021. Total 350 individuals with greater than or equal to 18 years of age, who were tested positive for Covid-19, were included. Patients who had received two doses of the vaccine at least 28 days apart were considered as vaccinated. The Sinopharm vaccination status was checked among patients. The severity of Covid-19 was categorized as mild, moderate and severe. A log rank regression test was applied to determine significant difference in disease severity and survival rate.
The patients age range was 25-60 years (the patients mean age was 55 years). The majority of participants, 69.1% (n=242), were vaccinated by Sinopharm, and 30.9% (n=108) were non-vaccinated. Most patients had mild disease 80% (n=280) followed by moderate disease 9.7% (n=34), and severe disease 6.6% (n=23), and stratification analysis had significant (p ≤ 0.05) association between vaccinated individuals and disease severity. The overall mortality rate was 3.7%. The mortality rate was 8% (n=9) in none vaccinated individuals, whereas 1.65% (n=4) in vaccinated individuals. The Sinopharm vaccine after both doses was found effective in reducing mortality and disease severity by 98.3% and 94.4%.
The study concluded that Sinopharm vaccine after two doses at least 28 days apart given to patients, after two weeks of vaccination is highly effective in reducing the mortality, disease severity and hospital admission in Covid-19 positive patients.

Keywords

Main Subjects

References

  1. Ahmad T, Haroon H, Dhama K, Sharun K, Khan FM, Ahmed I, et al. Biosafety and biosecurity approaches to restrain/contain and counter SARS-CoV-2/COVID-19 pandemic: a rapid-review. Turk J Biol. 2020;44(7):132-145.
  2. World Health Organization (WHO). WHO Coronavirus (COVID-19) Dashboard. 2023.
  3. El-Shabasy RM, Nayel MA, Taher MM, Abdelmonem R, Shoueir KR. Three waves changes, new variant strains, and vaccination effect against COVID-19 pandemic. Int J Biol Macromol. 2022;204(4):161-168.
  4. Mazagatos C, Monge S, Olmedo C, Vega L, Gallego P, Martín-Merino E, et al. Effectiveness of mRNA COVID-19 vaccines in preventing SARS-CoV-2 infections and COVID-19 hospitalisations and deaths in elderly long-term care facility residents, Spain, weeks 53 2020 to 13 2021. Euro Surveill. 2021;26(24):2100452.
  5. Citaristi I. World Health Organization—WHO. In The Europa Directory of International Organizations. 2022;2022:380-395. Routledge.
  6. Hunter DJ, Abdool Karim SS, Baden LR, Farrar JJ, Hamel MB, Longo DL, et al. Addressing vaccine inequity-Covid-19 vaccines as a global public good. N Engl J Med. 2022;386(12):1176-1179.
  7. Fiolet T, Kherabi Y, MacDonald CJ, Ghosn J, Peiffer-Smadja N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clin Microbiol Infect. 2022;28(2):202-221.
  8. Farrenkopf PM. Focus: Vaccines: The Cost of Ignoring Vaccines. Yale J Biol Med. 2022;95(2):265-269.
  9. Siddique S, Ahmed S. COVID-19 Vaccines in Pakistan: Efficacy, adverse effects and availability. J Islamabad Med Dent Coll. 2021;10(2):125-130.
  10. Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA. 2021;326(1):35-45.
  11. Shah SA, Arshad N, Asim F, Nadeem M. Prediction of Covid-19 infection severity using ABO blood group types and Rh factor. Pak J Med Sci. 2022;38(7):1870-1876.
  12. Rodewald LE. Doing the almost impossible job of fully immunizing every child. Acad Pediatr. 2021;21(4):S7-S8.
  13. Vokó Z, Kiss Z, Surján G, Surján O, Barcza Z, Pályi B, et al. Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary—the HUN-VE study. Clin Microbiol Infect. 2022;28(3):398-404.
  14. Nadeem I, Ul Munamm SA, Ur Rasool M, Fatimah M, Abu Bakar M, Rana ZK, et al. Safety and efficacy of Sinopharm vaccine (BBIBP-CorV) in elderly population of Faisalabad district of Pakistan. Postgrad Med J. 2023;99(1171):463-469.
  15. Holt SG, Mahmoud S, Ahmed W, Acuna JM, Al Madani AK, Eltantawy I, et al. An analysis of antibody responses and clinical sequalae of the Sinopharm HB02 COVID19 vaccine in dialysis patients in the United Arab Emirates. Nephrology. 2022;27(3):260-268.
  16. Chung H, He S, Nasreen S, Sundaram ME, Buchan SA, Wilson SE, et al. Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study. BMJ. 2021;374(8):n1943.
  17. AlHosani FI, Stanciole AE, Aden B, Timoshkin A, Najim O, Zaher WA, et al. Impact of the Sinopharm’s BBIBP-CorV vaccine in preventing hospital admissions and death in infected vaccinees: Results from a retrospective study in the emirate of Abu Dhabi, United Arab Emirates (UAE). Vaccine. 2022;40(13):2003-2010.
  18. Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397(10287):1819-1829.
  19. Zhang Y, Belayachi J, Yang Y, Fu Q, Rodewald L, Li H, et al. Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco. BMC Public Health. 2022;22(1):1584.
  20. Stoliaroff-Pepin A, Peine C, Herath T, Lachmann J, Perriat D, Dörre A, et al. Effectiveness of vaccines in preventing hospitalization due to COVID-19: A multicenter hospital-based case-control study, Germany, June 2021 to January 2022. Vaccine. 2023;41(2):290-293.
  21. Rahmani K, Shavaleh R, Forouhi M, Disfani HF, Kamandi M, Oskooi RK, et al. The effectiveness of COVID-19 vaccines in reducing the incidence, hospitalization, and mortality from COVID-19: A systematic review and meta-analysis. Front Public Health. 2022;10:2738.
  22. Feikin DR, Higdon MM, Abu-Raddad LJ, Andrews N, Araos R, Goldberg Y, Groome MJ, Huppert A, O'Brien KL, Smith PG, Wilder-Smith A. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022;399(10328):924-944.
Archives of Razi Institute
Volume 79, Issue 5
September and October 2024
Pages 967-972

Files

Share

How to cite

Statistics